ES2585242T3 - Cepas virales obtenidas del virus vaccinia Lister VACV-107 y usos de las mismas - Google Patents

Cepas virales obtenidas del virus vaccinia Lister VACV-107 y usos de las mismas Download PDF

Info

Publication number
ES2585242T3
ES2585242T3 ES09783172.1T ES09783172T ES2585242T3 ES 2585242 T3 ES2585242 T3 ES 2585242T3 ES 09783172 T ES09783172 T ES 09783172T ES 2585242 T3 ES2585242 T3 ES 2585242T3
Authority
ES
Spain
Prior art keywords
sequence
nucleotides
deletion
vacv
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09783172.1T
Other languages
English (en)
Inventor
Jean-Marc Crance
Daniel Garin
Daniele Gratier
Anne-Laure Favier
Robert Drillien
Matthias Hebben
Daniele Spehner
Karine Pradeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Service de Sante des Armees
Original Assignee
Service de Sante des Armees
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Service de Sante des Armees filed Critical Service de Sante des Armees
Application granted granted Critical
Publication of ES2585242T3 publication Critical patent/ES2585242T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una cepa viral obtenida del virus vaccinia Lister VACV-107 en la que la cepa contiene en su secuencia genómica de SEQ ID Nº1 las deleciones seleccionadas del grupo que consiste en: - deleción de los nucleótidos 19758 a 28309 en la secuencia ID NOº1 (Δ18) y deleción de los nucleótidos 161293 a 164811 en la secuencia ID NOº1 (Δ20), - deleción de los nucleótidos 19758 a 28309 en la secuencia ID NOº1 (Δ18) y deleción de los nucleótidos 6118 a 9677 en la secuencia ID NOº1 (Δ22), - deleción de los nucleótidos 19758 a 28309 en la secuencia ID NOº1 (Δ18), deleción de los nucleótidos 161293 a 164811 en la secuencia ID NOº1 (Δ20) y deleción de los nucleótidos 6118 a 9677 en la secuencia ID NOº1 (Δ22), - deleción de los nucleótidos 19758 a 28309 en la secuencia ID NOº1 (Δ18), deleción de los nucleótidos 181231 a 183304 en la secuencia ID NOº1 (Δ21), deleción de los nucleótidos 6118 a 9677 en la secuencia ID NOº1 (Δ22) y deleción de los nucleótidos 1833 a 3574 y 185848 a 187589 en la secuencia ID NOº1 (Δ23), - deleción de los nucleótidos 19758 a 28309 en la secuencia ID NOº1 (Δ18), deleción de los nucleótidos 161293 a 164811 en la secuencia ID NOº1 (Δ20), deleción de los nucleótidos 181231 a 183304 en la secuencia ID NOº1 (Δ21) y deleción de los nucleótidos 1833 a 3574 y 185848 a 187589 en la secuencia ID NOº1 (Δ23), y - deleción de los nucleótidos 19758 a 28309 en la secuencia ID NOº1 (Δ18), deleción de los nucleótidos 161293 a 164811 en la secuencia ID NOº1 (Δ20), deleción de los nucleótidos 181231 a 183304 en la secuencia ID NOº1 20 (Δ21), deleción de los nucleótidos 6118 a 9677 en la secuencia ID NOº1 (Δ22) y deleción de los nucleótidos 1833 a 3574 y 185848 a 187589 en la secuencia ID NOº1 (Δ23).
ES09783172.1T 2008-09-19 2009-09-18 Cepas virales obtenidas del virus vaccinia Lister VACV-107 y usos de las mismas Active ES2585242T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08305570 2008-09-19
EP08305570 2008-09-19
PCT/EP2009/062114 WO2010031837A1 (en) 2008-09-19 2009-09-18 Viral strains derived from the vaccinia virus lister vacv-107 and uses thereof

Publications (1)

Publication Number Publication Date
ES2585242T3 true ES2585242T3 (es) 2016-10-04

Family

ID=39926470

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09783172.1T Active ES2585242T3 (es) 2008-09-19 2009-09-18 Cepas virales obtenidas del virus vaccinia Lister VACV-107 y usos de las mismas

Country Status (4)

Country Link
US (1) US8623381B2 (es)
EP (1) EP2326712B1 (es)
ES (1) ES2585242T3 (es)
WO (1) WO2010031837A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2097517B1 (en) 2006-10-16 2014-06-04 Genelux Corporation Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
CA2786333C (en) * 2010-01-28 2018-03-20 Bavarian Nordic A/S Vaccinia virus mutants containing the major genomic deletions of mva
ES2733211T3 (es) * 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
KR101623498B1 (ko) * 2014-10-16 2016-05-24 대한민국 약독화 백시니아 바이러스주 kvac１０３
KR101645642B1 (ko) 2014-10-16 2016-08-11 대한민국 Kvac１０３ 유래의 재조합 백시니아 바이러스
KR101754756B1 (ko) * 2014-10-17 2017-07-07 대한민국 재조합 백시니아바이러스를 이용한 탄저/두창 2가 백신후보주
GB201816547D0 (en) * 2018-10-10 2018-11-28 Univ London Queen Mary Oncolytic virus for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420160T1 (de) * 2003-06-18 2009-01-15 Genelux Corp Modifizierte rekombinante vacciniaviren, verwendungen davon

Also Published As

Publication number Publication date
US8623381B2 (en) 2014-01-07
WO2010031837A1 (en) 2010-03-25
EP2326712A1 (en) 2011-06-01
EP2326712B1 (en) 2016-05-04
US20110171256A1 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
ES2585242T3 (es) Cepas virales obtenidas del virus vaccinia Lister VACV-107 y usos de las mismas
CL2009002207A1 (es) Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
AR053914A1 (es) Cepa atenuada del dengue serotipo 2
Ptáčková et al. Evolution of Archamoebae: morphological and molecular evidence for pelobionts including Rhizomastix, Entamoeba, Iodamoeba, and Endolimax
CL2016001580A1 (es) Uso de compuestos derivados de indol para tratar una infección por flavivirus; compuestos derivados de indol; composiciones farmacéuticas; y uso de una combinación.
AR082530A1 (es) Polinucleotidos y polipeptidos aislados, y metodos para utilizarlos para aumentar la eficacia en el uso de nitrogeno, rendimiento, tasa de crecimiento, vigor, biomasa, contenido de aceite y/o tolerancia al estres abiotico
AR103927A1 (es) Método para mejorar la habilidad de resistir a adn de virus que infectan plantas
CL2008001991A1 (es) Uso de homo y copolimeros que comprenden al menos 10% en peso de un monomero seleccionado entre acido acrilico y metacrilico y hasta 90% de uno o mas monomeros no ionicos, donde la suma de ambos es de al menos el 70% de los monomeros; composicion y preparacion del principio activo; dispersion acuosa y su preparacion.
UY33654A (es) Gen rf4 restaurador de esterilidad masculina citoplasmática (cms) tipo c en el maíz, marcadores mol eculares y uso de los mismos
AR053913A1 (es) Cepa atenuada de dengue serotipo 1
MX2009012451A (es) Plantas con rasgos mejorados relacionados con el rendimiento y un metodo para producirlas.
UY35088A (es) Inhibidores de glutamina sintetasa de planta y métodos para su identificación
AR109941A1 (es) Generación de maíz resistente al tizón de la hoja del norte
TR201819340T4 (tr) IB-QX Benzeri Suşlardan Türetilmiş Enfeksiyöz Bronşit Aşıları
MX387420B (es) Producción de virus en cultivos celulares.
AR089784A1 (es) EVENTO DE ALGODON RESISTENTE A HERBICIDA pDAB4468.18.07.1
AR098660A1 (es) Composiciones y métodos para seleccionar plantas de maíz resistentes a la podredumbre del tallo por antracnosis
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
AR059005A1 (es) Virus quimericos del dengue
CL2013002723A1 (es) Metodo de produccion de una particula semejante a virus (vlp) de alfavirus salmonido (sav) en celulas de insecto.
AR061197A1 (es) Cepas del virus 3 del dengue vivas atenuadas
AR066823A1 (es) Aumento del rendimiento en plantas por modulacion del factor zmrr10-p de transcripcion de garp
Velázquez et al. Association of citrus psorosis B symptoms with a sequence variant of the Citrus psorosis virus RNA 2
MA32305B1 (fr) Vaccin contre le virus vivant attenue inactive de la fievre catarrhale ovine
PE20090214A1 (es) Perfil de temperatura de dos etapas para la propagacion de los virus